Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centre

DC FieldValueLanguage
dc.contributor.authorMartin, William P.-
dc.contributor.authorBauer, Jessica-
dc.contributor.authorColeman, John-
dc.contributor.authorDellatorre-Teixeira, Ludmilla-
dc.contributor.authorReeve, Janice L. V.-
dc.contributor.authorTwomey, Patrick J.-
dc.contributor.authorDocherty, Neil G.-
dc.contributor.authorO'Riordan, Aisling-
dc.contributor.authorWatson, Alan J.-
dc.contributor.authorle Roux, Carel W.-
dc.contributor.authorHolian, John-
dc.date.accessioned2021-11-23T13:06:16Z-
dc.date.available2021-11-23T13:06:16Z-
dc.date.copyright2020 the Authorsen_US
dc.date.issued2020-12-
dc.identifier.citationClinical obesityen_US
dc.identifier.issn1758-8103-
dc.identifier.urihttp://hdl.handle.net/10197/12668-
dc.description.abstractObesity is a treatable risk factor for chronic kidney disease progression. We audited the reporting of body-mass index in nephrology outpatient clinics to establish the characteristics of individuals with obesity in nephrology practice. Body-mass index, clinical information and biochemical measures were recorded for patients attending clinics between 3rd August, 2018 and 18th January, 2019. Inferential statistics and Pearson correlations were used to investigate relationships between body-mass index, type 2 diabetes, hypertension and proteinuria. Mean ± SD BMI was 28.6 ± 5.8 kg/m2 (n = 374). Overweight and obesity class 1 were more common in males (P = .02). Amongst n = 123 individuals with obesity and chronic kidney disease, mean ± SD age, n (%) female and median[IQR] eGFR were 64.1 ± 14.2 years, 52 (42.3%) and 29.0[20.5] mL/min/BSA, respectively. A positive correlation between increasing body-mass index and proteinuria was observed in such patients (r = 0.21, P = .03), which was stronger in males and those with CKD stages 4 and 5. Mean body-mass index was 2.3 kg/m2 higher in those treated with 4-5 versus 0-1 antihypertensives (P = .03). Amongst n = 59 patients with obesity, chronic kidney disease and type 2 diabetes, 2 (3.5%) and 0 (0%) were prescribed a GLP-1 receptor analogue and SGLT2-inhibitor, respectively. Our data provides a strong rationale not only for measuring body-mass index but also for acting on the information in nephrology practice, although prospective studies are required to guide treatment decisions in people with obesity and chronic kidney disease.en_US
dc.description.sponsorshipHealth Research Boarden_US
dc.description.sponsorshipHealth Service Executiveen_US
dc.description.sponsorshipScience Foundation Irelanden_US
dc.description.sponsorshipWellcome Trusten_US
dc.format.mediumPrint-Electronic-
dc.language.isoenen_US
dc.publisherWileyen_US
dc.rightsThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.en_US
dc.subjectDiabetes mellitusen_US
dc.subjectDiabetic kidney diseaseen_US
dc.subjectObesityen_US
dc.subjectOverweighten_US
dc.subjectBariatric surgeryen_US
dc.subjectSGLT2 inhibitorsen_US
dc.subjectGlomerulopathyen_US
dc.subjectLiraglutideen_US
dc.subjectMortalityen_US
dc.subjectTrialsen_US
dc.titleObesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in a tertiary nephrology centreen_US
dc.typeJournal Articleen_US
dc.internal.authorcontactotherwilliam.martin@ucd.ieen_US
dc.statusPeer revieweden_US
dc.identifier.volume10en_US
dc.identifier.issue6en_US
dc.citation.otherArticle Number: e12402en_US
dc.identifier.doi10.1111/cob.12402-
dc.neeo.contributorMartin|William P.|aut|-
dc.neeo.contributorBauer|Jessica|aut|-
dc.neeo.contributorColeman|John|aut|-
dc.neeo.contributorDellatorre-Teixeira|Ludmilla|aut|-
dc.neeo.contributorReeve|Janice L. V.|aut|-
dc.neeo.contributorTwomey|Patrick J.|aut|-
dc.neeo.contributorDocherty|Neil G.|aut|-
dc.neeo.contributorO'Riordan|Aisling|aut|-
dc.neeo.contributorWatson|Alan J.|aut|-
dc.neeo.contributorle Roux|Carel W.|aut|-
dc.neeo.contributorHolian|John|aut|-
dc.description.othersponsorshipEuropean Foundation for the Study of Diabetesen_US
dc.description.othersponsorshipSwedish Medical Research Councilen_US
dc.description.othersponsorshipBoehringer Ingelheim European Diabetes Research Programmeen_US
dc.date.updated2020-10-20T19:53:29Z-
dc.identifier.grantid12/YI/B2480-
dc.identifier.grantid2015-02733_VR-
dc.rights.licensehttps://creativecommons.org/licenses/by/3.0/ie/en_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Conway Institute Research Collection
Medicine Research Collection
Files in This Item:
 File SizeFormat
Downloadcob.12402.pdf1.64 MBAdobe PDF
DownloadCO manuscript 200806.docx2.34 MBUnknown
Show simple item record

Page view(s)

216
checked on Nov 30, 2021

Download(s)

19
checked on Nov 30, 2021

Google ScholarTM

Check

Altmetric


If you are a publisher or author and have copyright concerns for any item, please email research.repository@ucd.ie and the item will be withdrawn immediately. The author or person responsible for depositing the article will be contacted within one business day.